Kanvas Biosciences, a Monmouth Junction, NJ-based company which specializes in advancing microbiome mapping technology, raised $12M in Pre-Series A funding.
The round was led by DCVC with participation from Lions Capital LLC, Cooke LLC, Uncommon Denominator, and Triple Impact Capital. As part of the investment round, Jason Pontin, partner at DCVC, will join the company’s board of directors.
The company intends to use the funds to further advance its proprietary platform technology.
Led by CEO Matthew Cheng, Kanvas Biosciences is building a microbiome drug screening and drug discovery platform to accelerate live biotherapeutic product (LBP) development. Leveraging its ability to spatially map the microbiome and profile host-gene expression at single-cell resolution, the company is constructing a comprehensive microbiome data resource for future drug development.
The platform determines the identity and function of these microbes and maps the host’s corresponding local response – all executed within a single, comprehensive assay. It can be applied to the discovery and development of novel, live biotherapeutic products, the identification of disease-associated microbes for diagnostics, and leveraging the microbiome to improve therapeutic responses.
FinSMEs
22/06/2023